Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders

Rhea-AI Summary

Inspira (NASDAQ: IINN) said two previously announced binding purchase orders — $22.5 million (July 2, 2025) and $27 million (August 19, 2025) — have advanced to the final budgetary validation and fund allocation stage within relevant governmental procurement processes.

The company reported that ~91% of the orders have cleared commercial and administrative review and are undergoing the concluding budgetary authorization step prior to fund release and execution. Inspira expects payment and revenue recognition during the 2026 fiscal cycle, subject to customary governmental approvals, and says internal execution preparations are complete.

Positive

• Binding purchase orders totaling $49.5 million advanced to final budget stage
• ~91% cleared commercial and administrative review stages
• Payment and revenue recognition expected during the 2026 fiscal cycle

Negative

• Advancement is subject to final governmental approval before fund release
• Timing of payments depends on completing governmental budgetary cycles

Argus Jan 21 session

-4.57% close to close Open Argus

Details

News Market Reaction – IINN

In the Jan 21 session, IINN declined 4.57%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement advances Inspira’s previously disclosed $22.5 million and $27 million binding purc...

Analysis

This announcement advances Inspira’s previously disclosed $22.5 million and $27 million binding purchase orders to the final governmental budgetary validation step, with about 91% of the value already through earlier reviews. Payment and revenue remain tied to the 2026 fiscal cycle. Recent history includes reaffirmation of $49.5 million in orders and new financing capacity, including a shelf of up to $75,000,000. Investors may watch for completed approvals, cash usage, and any further equity draws.

Key Figures

Binding purchase order 1: $22.5 million Binding purchase order 2: $27 million Order review progress: 91% +5 more

Binding purchase order 1

$22.5 million

Order announced July 2, 2025; now at final budgetary validation

Binding purchase order 2

$27 million

Order announced August 19, 2025; now at final budgetary validation

Order review progress

91%

Portion of orders cleared commercial and administrative review

Revenue timing

2026 fiscal cycle

Expected payment and revenue recognition for binding orders

Shelf registration size

$75,000,000

Maximum aggregate amount under Form F-3 shelf filed Nov 25, 2025

Planned equity investment

$15 million

Concurrent investment linked to liquid biopsy acquisition term sheet

Pre-money valuation

$180 million

Valuation basis for proposed $15 million equity investment

Legacy tech funding

$12 million

Portion of investment earmarked for existing respiratory and blood-monitoring tech

Historical Context

5 past events · Latest: Jan 08

5 events

1. Jan 08

   Strategic vision update

   24h Move

   -0.2%

   Outlined liquid biopsy expansion and strategic transaction framework.

2. Jan 05

   Acquisition term sheet

   24h Move

   +7.8%

   Non-binding term sheet plus $15M strategic equity investment.

3. Jan 05

   Acquisition term sheet

   24h Move

   +7.8%

   All-share liquid biopsy acquisition and $15M investment announcement.

4. Dec 23

   Order reaffirmation

   24h Move

   -5.0%

   Reaffirmed $49.5M binding purchase orders for 2026 execution.

5. Dec 15

   Equity offering/SEPA

   24h Move

   -8.7%

   Registered direct equity offering and standby equity purchase agreement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RA'ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today provided an update highlighting significant progress in the execution of its previously announced binding purchase orders.

The Company has received a formal notification from its distribution partner that the $22.5 million and $27 million binding purchase orders, originally announced on July 2, 2025 and August 19, 2025, respectively, have advanced to the final budgetary validation and fund allocation stage within the relevant governmental authorities' procurement processes.

According to the notification, approximately 91% of the purchase orders have cleared commercial and administrative review stages and are now undergoing final budgetary authorization procedures, which represent the concluding administrative step before fund release and operational execution, subject to completion of customary governmental approval processes.

As previously disclosed in the Company's December 23, 2025 update, payment and revenue recognition relating to these purchase orders is expected during 2026 fiscal cycle, aligned with the completion of the governmental budgetary cycle and subsequent deployment milestones.

The Company has completed its internal preparations for execution and will provide further updates as material milestones are reached.

Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "We continue to work closely with our distribution partners and governmental stakeholders on the execution of these purchase orders. Advancement to the final budgetary stage is a procedural step in complex international procurement processes. We remain focused on converting our contracted backlog into delivered systems and recognized revenue."

About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.

Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the status, progression, and potential execution of its previously announced binding purchase orders, the completion of remaining governmental budgetary validation, authorization, and fund allocation procedures, the timing thereof, fund release, delivery, deployment, payment and revenue recognition related to these purchase orders, the Company’s operational readiness to execute and fulfill the agreements, and the conversion of its contracted backlog into delivered systems and recognized revenue. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.

Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What purchase orders did Inspira (IINN) advance on January 21, 2026?

Two binding purchase orders of $22.5M (July 2, 2025) and $27M (August 19, 2025) advanced to final budgetary validation.

How much of Inspira's (IINN) purchase orders have cleared administrative review?

Approximately 91% of the purchase orders cleared commercial and administrative review stages.

When does Inspira (IINN) expect payment and revenue recognition for these orders?

The company expects payment and revenue recognition during the 2026 fiscal cycle, aligned with governmental budget completion and deployment milestones.

Are Inspira's (IINN) purchase orders finalized and guaranteed?

The orders are binding but the final fund release and execution remain subject to customary governmental approval procedures.

What operational readiness has Inspira (IINN) reported for executing these orders?

Inspira said it has completed internal preparations for execution and will update on material milestones as reached.